Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections

Journal of Chemotherapy

Volumn 22, Issue 2, 2010, Pages 110-114

  Metan, Gokhan ^a   Alp, E ^a   Yildiz, O ^a   Percin, D ^a   Aygen, B ^a   Sumerkan, B ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Acinetobacter infections; Carbapenem resistance; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; LIOTHYRONINE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; MICROORGANISM; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; SURGICAL INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 77951555223     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.2.110     Document Type: Article

References (19)

1. French GL. A review of tigecycline. J Chemother 2008; 20 Suppl 1: 3-11.
2. Gamer JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-140
3. Kollef MH. Diagnosis of ventilator-associated pneumonia. N EngI J Med 2006; 355: 2691-2693
4. Anonymous. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare associated pneumonia. Am J Respir Crit Care Med 2005: 171: 388-416.
5. Levy MM, Fink MP, Marshall JC, Abraham E, Agnus D, Cook D, at al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31: 1250-1256
6. Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogans. J Infect 2009; 58(4): 273-284
7. British British Society for Antimicrobial Chemotherapy. BSAC Disc Diffusion Method for Antimicrobial Susceptibility Testing. Version 6.1 February 2007 http://www.bsac.org.uk 22 January 2008, data last accessed).
8. Galani I, Kontopidou F, Souli M, et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008; 31(5): 434-439
9. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63(4): 775-780
10. Metan G, Sar guzel F, Sumerkan B. Factors influencing the mortality in patients with multi-drug resistant Acinetobacter bacteraemia. Eur J Intern Med 2009; 20)5): 540-544
11. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug resistant (including carbapenem resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62(1): 45-55.
12. Gallagher JC. Rouse HM. Tigecycline for the treatment of Acinetobacter infections a case series. Ann Pharmacother 2008; 42(9): 1188-1194
13. Curcio D, Fernández F, Vergara J, Vazquez W, Luna CM. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009; 21(1): 58-62.
14. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T et al; 309 Study Group. A Phase 3, open label, non comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumonnii and Klebsiella pneumoniae. J Antimicrob Chemother 2008: 62 Suppl 1: i29-40.
15. Wadi JA, Al Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann Saudi Med 2007;27(6): 456-458
16. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21(3): 538 82.
17. Anthony KB. Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46(4): 567-570
18. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-1201
19. Fernández-Mazarrasa C, Mazarrasa O, Calvo J, del Arco A, Martínez-Martínez L. High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest. J Clin Microbiol. 2009; 47(3): 827-829